China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Employees

142

Sector

Healthcare Facilities & Services

More about the company

Quotes

Date	Price	Change	Volume
26-08-03	HK$0.6500	+4.84%	510,000
26-07-31	HK$0.6200	0.00%	555,000
26-07-30	HK$0.6200	0.00%	450,000
26-07-29	HK$0.6200	-4.62%	235,000
26-07-28	HK$0.6500	+8.33%	482,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 04:08:12 2026-08-03 EDT			5-day change	1st Jan Change
0.6500 ^HKD	+4.84%		+1.56%	-17.72%

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE

Market Cap	634M 80.88M 70.3M 65.48M 60.25M 114M 7.71B 116M 772M 303M 3.85B 304M 297M 12.71B	P/E 2024	-2.49x	P/E 2025	-11.2x
Enterprise Value	1.02B 130M 113M 105M 96.61M 182M 12.36B 185M 1.24B 486M 6.17B 487M 476M 20.39B	EV / Sales 2024	9.45x	EV / Sales 2025	15.7x
Free-Float	35.46%	Yield 2024 *	-	Yield 2025	-

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE
04-30	China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026	CI
04-28	China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
03-27	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	China Biotech Services expects FY net loss of not more than HK$100 million	RE
03-06	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025	CI
02-19	China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd	CI
12-29	China Biotech Services to issue convertible bonds	RE
12-28	China Biotech Services Holdings Limited announced that it expects to receive HKD 272.3 million in funding	CI
25-09-29	China Biotech Services says outstanding convertible bonds amount to $6 million	RE
25-09-11	China Biotech Services' unit enters loan contract with Hainan Rural Commercial Bank	RE
25-08-27	China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI

23-01-10	China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate	AQ
22-06-24	Sumitomo Heavy Industries, Ltd. - Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China	AQ
21-08-09	China Biotech Services : AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China	AQ
21-06-28	China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses	AQ
21-01-28	China Biotech Services : Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40	AQ

China Biotech Services Holdings Limited Stock

Stocks

8037

BMG2152F1014

Healthcare Facilities & Services

Valuation: China Biotech Services Holdings Limited

Chart: China Biotech Services Holdings Limited

Latest news : China Biotech Services Holdings Limited

Press Releases: China Biotech Services Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: China Biotech Services Holdings Limited

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+4.84%
1 week	+1.56%
Current month	+4.84%
1 month	+51.16%
3 months	-2.99%
6 months	-17.72%
Current year	-17.72%

1 week	0.59	0.69
1 month	0.42	0.73
Current year	0.3	0.92
1 year	0.3	1.33
3 years	0.25	1.33
5 years	0.25	2.64
10 years	0.16	2.64

Manager	Title	Age	Since
Xiao Lin Liu CMP	Compliance Officer	55	2022-05-25
Eddy Lai DFI	Director of Finance/CFO	-	-
Xuan ming Yang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Guo Xiang Yan BRD	Director/Board Member	60	2017-08-06
Song Huang BRD	Director/Board Member	44	2017-09-14
Xiao Lin Liu CHM	Chairman	55	2017-08-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/2/24	Xun He	Other	Director	3,220,000	0.3300%
6/13/24	Hoi Yam Chui	Other	Director	5,000,000	0.5191%
1/19/24	Xiao Lin Liu	Other	Chairman	30,000	0.0031%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA BIOTECH SERVICES HOLDINGS LIMITED	+4.84%	+1.56%	+1.56%	-5.80%	77.15M
CVS HEALTH CORPORATION	+0.90%	-2.20%	+68.67%	+37.90%	133B
HCA HEALTHCARE, INC.	+1.00%	+6.39%	+13.91%	+50.94%	87.16B
FRESENIUS SE & CO. KGAA	+0.56%	+2.21%	+8.96%	+56.70%	28.85B
QUEST DIAGNOSTICS INCORPORATED	-0.45%	+1.79%	+35.76%	+72.12%	25.72B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.49%	+6.97%	-9.23%	-16.55%	21.85B
TENET HEALTHCARE CORPORATION	-1.88%	+7.20%	+58.13%	+237.37%	20.51B
DAVITA INC.	-2.67%	-0.75%	+68.75%	+129.17%	15.41B
REDE D'OR SÃO LUIZ S.A.	-1.67%	+1.37%	+2.59%	-1.39%	14.98B
FRESENIUS MEDICAL CARE AG	+0.92%	+3.67%	+3.65%	-3.19%	13.55B
Average	+0.30%	+2.62%	+25.27%	+55.73%	36.14B
Weighted average by Cap.	+0.42%	+1.64%	+37.85%	+53.73%

	2024	2025
Net sales	70.51M 8.99M 7.82M 7.28M 6.7M 12.63M 857M 12.85M 85.84M 33.67M 428M 33.77M 33.02M 1.41B	73.5M 9.37M 8.15M 7.59M 6.98M 13.16M 894M 13.4M 89.49M 35.1M 446M 35.2M 34.43M 1.47B
Net income	-198M -25.27M -21.96M -20.46M -18.82M -35.48M -2.41B -36.12M -241M -94.61M -1.2B -94.89M -92.81M -3.97B	-68.78M -8.77M -7.62M -7.1M -6.53M -12.32M -836M -12.54M -83.74M -32.84M -417M -32.94M -32.21M -1.38B
Net Debt	169M 21.54M 18.72M 17.44M 16.05M 30.25M 2.05B 30.79M 206M 80.65M 1.02B 80.89M 79.12M 3.39B	383M 48.82M 42.43M 39.52M 36.37M 68.55M 4.65B 69.77M 466M 183M 2.32B 183M 179M 7.67B